Stephen B Howell

US Patent:

6344324, Feb 5, 2002

Filed:

Jan 7, 2000

Appl. No.:

09/479529

Inventors:

Stephen B. Howell - Del Mar CA
Xinjian Lin - San Diego CA
Dennis P. Gately - San Diego CA

Assignee:

Research Development Foundation - Carson City NV

International Classification:

C12Q 168

US Classification:

435 6, 435 29, 435366, 435371

Abstract:

The present invention features a novel cellular injury reporter system in which a chimeric gene containing the GADD153 promoter linked to the coding region of an enhanced green fluorescent protein (EGFP) gene was stably integrated into the genome of carcinoma cells. Activation of the GADD153 promoter was quantified using flow cytometric measurement of EGFP expression following drug exposure. This reporter system is suitable for high. throughput in vitro and in vivo screening for agents capable of producing cytotoxicity via a wide variety of different mechanisms, and can be utilized to investigate the relative potency of structurally related DNA adducts.

US Patent:

8575359, Nov 5, 2013

Filed:

Apr 4, 2007

Appl. No.:

12/295858

Inventors:

Jerry Yang - La Jolla CA, US
Seong Deok Kong - La Jolla CA, US
Alice Luong - San Diego CA, US
Stephen Howell - Del Mar CA, US

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C07D 233/00
C07D 233/02
C07D 233/54
C07D 233/60
C07H 15/24

US Classification:

5483001, 5483415, 536 64

Abstract:

The invention is in general directed to acid-sensitive linkers, and methods of use thereof, such as, for example, in drug delivery methods.

US Patent:

20060019268, Jan 26, 2006

Filed:

Mar 28, 2005

Appl. No.:

11/091938

Inventors:

Timothy Cheng - Toronto, CA
Stephen Howell - Del Mar CA, US
Gerald Manorek - San Diego CA, US
Charles Berry - San Diego CA, US
Goli Samimi - Los Angeles CA, US

International Classification:

C12Q 1/68

US Classification:

435006000

Abstract:

The present invention relates generally to the fields of molecular biology and medicine. More particularly, it concerns cancer treatments and the identification and use of markers for cancer resistance to a platinum-drug based therapy therapy. In certain embodiments, the present invention provides diagnostic and/or prognostic methods involving a collection of differentially expressed genes that may be used to identify cisplatin resistance in human ovarian cancer.

US Patent:

56747136, Oct 7, 1997

Filed:

Jun 2, 1995

Appl. No.:

8/460214

Inventors:

Marlene DeLuca McElroy - late of La Jolla CA
Donald Raymond Helinski - La Jolla CA
Keith Vernon Wood - San Diego CA
Jeffrey Roux De Wet - Menlo Park CA
David Wing Ow - San Francisco CA
Stephen Herbert Howell - Del Mar CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 121
C12N 510
C12N 1553
C12N 902

US Classification:

435 697

Abstract:

DNA compositions and methods of constructing and using the same consisting of DNA sequences encoding luciferase activity, or DNA sequences encoding hybrid molecules exhibiting luciferase activity and a second biological activity that are useful in performing biological assays.

US Patent:

58075720, Sep 15, 1998

Filed:

Jun 6, 1995

Appl. No.:

8/473019

Inventors:

Sinil Kim - Solana Beach CA
Stephen B. Howell - Del Mar CA

Assignee:

DepoTech Corporation - La Jolla CA

International Classification:

A61K 9127

US Classification:

424450

Abstract:

Disclosed are multivesicular liposomes containing biologically active substances, the multivesicular liposomes having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a modulated rate of the biologically active substance in contrast to the previous art. The process comprises dissolving a lipid component in volatile organic solvents, adding an immiscible aqueous component containing at least one biologically active substance to be encapsulated, and adding to either or both the organic solvents and the lipid component, a hydrochloride effective to control the release rate of the biologically active substance from the multivesicular liposome, making a water-in-oil emulsion from the two components, immersing the emulsion into a second aqueous component, dividing the emulsion into small solvent spherules which contain even smaller aqueous chambers, and then removing the solvents to give an aqueous suspension of multivesicular liposomes encapsulating biologically active substances.

US Patent:

60715340, Jun 6, 2000

Filed:

Feb 5, 1998

Appl. No.:

9/019337

Inventors:

Sinil Kim - Solana Beach CA
Stephen B. Howell - Del Mar CA

Assignee:

SkyePharma Inc. - San Diego CA

International Classification:

A61K 9127

US Classification:

424450

Abstract:

Disclosed are multivesicular liposomes containing biologically active substances, and having defined size distribution, adjustable average size, adjustable internal chamber size and number, and a modulated release of the biologically active substance. The liposomes are made by a process comprising dissolving a lipid component in volatile organic solvents, adding an immiscible aqueous component containing at least one biologically active substance to be encapsulated, and adding to either or both the organic solvents and the lipid component, a hydrochloride effective to control the release rate of the biologically active substance from the multivesicular liposome. A water-in-oil emulsion is made from the two components, the emulsion is immersed into a second aqueous component, and then divided into small solvent spherules which contain even smaller aqueous chambers. The solvents arc finally removed to give an aqueous suspension of multivesicular liposomes encapsulating biologically active substances.

US Patent:

58440011, Dec 1, 1998

Filed:

Dec 2, 1994

Appl. No.:

8/348307

Inventors:

Edward F. McClay - Charleston SC
Stephen B. Howell - Del Mar CA
Gerrit Los - San Diego CA

Assignee:

Research Development Foundation - Carson City NV

International Classification:

A61K 31135
A61K 3128
A61K 3324

US Classification:

514648

Abstract:

The present invention provides a composition of matter for the treatment of non-melanoma cancers, wherein said composition comprises a platinum anti-neoplastic compound and tamoxifen, wherein said platinum anti-neoplastic compound and tamoxifen exert a synergistic anti-tumor effect on said non-melanoma cancer. Also provided are various methods of treating non-melanoma cancers and methods of preventing or overcoming resistance to platinum-containing anti-neoplastic compounds.

US Patent:

55830242, Dec 10, 1996

Filed:

May 10, 1993

Appl. No.:

8/060091

Inventors:

Marlene D. McElroy - late of La Jolla CA
W. D. McElroy - San Diego CA
Donald R. Helinski - La Jolla CA
Keith V. Wood - San Diego CA
Jeffrey R. De Wet - Menlo Park CA
David W. Ow - San Francisco CA
Stephen H. Howell - Del Mar CA

Assignee:

The Regents of the University of California - Oakland CA

International Classification:

C12N 902
C12N 1553
C12N 1563

US Classification:

135189

Abstract:

A method is disclosed for producing a protein which expresses bioluminescence activity which involves combining two polydeoxyribonucleotides, one containing a continuous sequence of codons encoding a polypeptide which comprises a single covalently bonded molecular structure and which catalyzes the oxidation of insect luciferin to yield light and the other which causes DNA transcription, and obtaining the polypeptide by transcription and subsequent translation. The insect luciferin is derived from bioluminescent insect, preferably Diptera and Coleoptera (fireflies and beetles). Hybrid proteins are similarly formed by inclusion of an additional polydeoxyribonucleotide encoding for a second polypeptide such that their respective polypeptide-encoding reading frames form a continuous reading frame. Also disclosed is a method for quantitatively assaying a fluid for the presence of an unknown quantity of antigen using the hybrid proteins bonded to antibody directed against the antigen, determining luminescence after reaction of the antibody and antigen, and determining the amount of the antigens by comparison of the determined luminescence with the luminescence previously measured under equivalent conditions for equivalent hybrid proteins reacted under equivalent conditions with known amounts of the antigen.